VERA THERAPEUTICS INC
VERANASDAQTrading Snapshot
- Day Range
- $30.31 – $30.99
- 52-Week Range
- $19.25 – $56.05
- Volume
- $2.90B
- Avg Volume
- $2.80B
- Shares Outstanding
- 71.8M
- Next Earnings
- Oct 6, 2026
Fundamentals Snapshot
- Annual Revenue
- $525M
- Last Q Revenue
- $128M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-5.54
- Dividend Yield
- —
Why Investors Own VERA
- ✓High-growth profile — revenue up +10.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 47% gross margin and 8% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About VERA THERAPEUTICS INC
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Wedbush Maintains Neutral on Vera Therapeutics, Lowers Price Target to $34
Wedbush analyst Laura Chico maintains Vera Therapeutics (NASDAQ:VERA) with a Neutral and lowers the price target from $43 to $34.
Vera Therapeutics Q2 EPS $(1.52) Beats $(1.61) Estimate
Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(1.52) per share which beat the analyst consensus estimate of $(1.61) by 5.59 percent. This is a 26.67 percent decrease over losses of $(1.20) per share from